SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,235.00
+20.00 (0.90%)
Sep 22, 2026, 3:30 PM KST
SillaJen Revenue
SillaJen had revenue of 2.24B KRW in the quarter ending June 30, 2026, a decrease of -6.19%. This brings the company's revenue in the last twelve months to 10.77B, up 69.18% year-over-year. In the year 2025, SillaJen had annual revenue of 9.23B with 134.94% growth.
Revenue (ttm)
10.77B
Revenue Growth
+69.18%
P/S Ratio
28.75
Revenue / Employee
188.98M
Employees
57
Market Cap
309.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.23B | 5.30B | 134.94% |
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 345.88B |
| Medy-Tox | 251.08B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| HLB Therapeutics | 64.45B |
| GC Genome | 32.64B |
| AbClon | 5.31B |